Sales in WHIM syndrome are not expected to be huge ... Meanwhile, the approval means X4 also gets a coveted priority review voucher from the FDA that can be used to reduce the standard review ...

The FDA has started a priority review of X4 Pharma’s mavorixafor, angling to become the first therapy for the rare disease WHIM syndrome, with a decision due by 30th April next year. WHIM (warts ...